Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis

NCT00367484 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

BIOLOGICAL: Rebif® (clone 484-39)

Sponsor

Merck KGaA, Darmstadt, Germany